COMP <GO>
TMDX vs CNMD // EV/EBITDA & P/E VALUATION
TransMedics Group Inc. (NASDAQ) VS. CONMED Corporation (NYSE) • 15-METRIC TALLY: TMDX 9
— CNMD 4
▲ EV/EBITDA & P/E VALUATION LEADER: CNMD
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
valuation
14.6x
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
valuation
11.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. CNMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | CNMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 54.60% | +5.30 | TMDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 7.80% | +10.30 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 14.6x | 11.4x | +3.20 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | 11.07% | -5.33 | CNMD | /fcf-yield <GO> |
| Operating Margin | 17.90% | 7.50% | +10.40 | TMDX | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 3.40% | +28.00 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 5.20% | +31.90 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.82% | -1.82 | CNMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 1.91 | +1.59 | TMDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 28.9 | 40.6 | -11.67 | CNMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | 26.9x | -16.70 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $1.36B | $964.8M | TMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | CNMD REV | TMDX GROSS % | CNMD GROSS % | TMDX FCF | CNMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $1.37B | 59.9% | 54.6% | $133.6M | $150.9M |
| FY 2024 | $441.5M | $1.31B | 59.4% | 56.1% | -$80.9M | $153.9M |
| FY 2023 | $241.6M | $1.24B | — | — | -$13.0M | $125.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
CNMD // BETA —